Petra Malátková

Petra Malátková

Auto-generated profile, based on publicly available information

Petra Malátková

Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, CZ-50005 Hradec Králové, Czech Republic

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2013 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
PMPetra Malátková
Petra Malátková
VWVladimír Wsól
Vladimír Wsól
The understanding of drug biotransformation is an important medical topic. The oxidative pathways that involve CYPs have been extensively studied in drug metabolism in contrast to the reductive pathways. This review focuses on drugs that have been reported to be reduced at the carbonyl group in vivo. Although the carbonyl reduction of these drugs is well known, our understanding of the carbonyl reducing enzymes (CRE) that perform these reactions is limited. We have summarized the published data in order to thoroughly describe the reductive metabolism of the selected drugs and to demonstrate the role of carbonyl reduction in the context of their overall metabolism. The number of drugs recognized as substrates for CREs has increased considerably in recent years. Moreover, the importance of carbonyl reduction in the overall metabolism of these drugs is often surprisingly high. Because only limited information is available about the CREs responsible for these reactions, additional research is needed to improve our understanding of the metabolism of drugs undergoing carbonyl reduction. Carbonyl reduction should be investigated during drug development because it can either positively or negatively influence drug efficacy.

1 October 2010 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
PMPetra Malatkova
Petra Malatkova
EMEdmund Maser
Edmund Maser
VWVladimír Wsól
Vladimír Wsól
Enzymatic carbonyl reduction means the formation of a hydroxy function out of a ketone or aldehyde moiety and applies for the metabolism of physiological (endogenous) or xenobiotic (exogenous) molecules. As for endogenous substrates, carbonyl reduction is often part of a reversible oxidoreductase process and involves the activation or inactivation of important signal molecules like steroids, prostaglandins, retinoids and biogenic amines. These reactions are carried out by NAD(P)(H)-dependent dehydrogenases belonging to two protein superfamilies, the aldo-keto reductases (AKR) and the short-chain dehydrogenases/reductases (SDR). With regard to exogenous substrates, carbonyl reduction of xenobiotics is generally a “one-way” detoxification reaction, since the resulting alcohol is easier to conjugate and to eliminate. Interestingly, the participating enzymes do also belong to the AKR and SDR superfamilies. Moreover, some enzymes from the two protein superfamilies exhibit pluripotency in that they are able to catalyze the oxidoreduction of endobiotics but do also function in the reductive metabolism of carbonyl group bearing xenobiotics. A special case are carbonyl reductases per se which belong to the SDR superfamily and whose substrates or physiological roles are not quite clear. Usually, carbonyl reductases have a broad and diverse substrate spectrum for xenobiotics, however, for some of them a specific physiological function has been speculated. In the human genome, three SDR genes have been identified to code for the carbonyl reductases CBR1 (SDR21C1), CBR3 (SDR21C2) and CBR4 (SDR45C1). The present review summarizes the current knowledge on these enzymes with special emphasis on their role as a defence system against toxicants, as well as their possible physiological function and medical application. In detail, we have screened the recent literature on these three enzymes with regard to endogenous and exogenous substrates, their three-dimensional structure, tissues specific expression, polymorphisms, transcriptional regulation, occurrence in pathological states, and their possible association with cancer. Combined, this review contributes to understanding the complex nature and biological role(s) of the human carbonyl reductases CBR1, CBR3 and CBR4.

31 August 2010 in Biochemistry
Verified
Journal Article
Closed access
BEBettina Ebert
Bettina Ebert
MKMichael Kisiela
Michael Kisiela
PMPetra Malátková
Petra Malátková
YEYasser El-Hawari
Yasser El-Hawari
EMEdmund Maser
Edmund Maser

1 September 2014 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
PMPetra Malátková
Petra Malátková
LHLucie Havlíková
Lucie Havlíková
VWVladimír Wsól
Vladimír Wsól

1 June 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
PMPetra Malátková
Petra Malátková
SSSimona Sokolová
Simona Sokolová
LHLucie Chocholoušová Havlíková
Lucie Chocholoušová Havlíková
VWVladimír Wsól
Vladimír Wsól

1 April 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
PMPetra Malátková
Petra Malátková
BEBettina Ebert
Bettina Ebert
VWVladimír Wsól
Vladimír Wsól
EMEdmund Maser
Edmund Maser